Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other jurisdiction o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other juris ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number 001-35023 iBio, Inc. (Exact name of registrant as specified in its charter) Delaware 26-2797813 (State or other ju ...

iBio, Inc. (NYSE:IBIO) Q4 2022 Earnings Conference Call September 27, 2022 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman and Chief Executive Officer Rob Lutz - Chief Financial and Business Officer Martin Brenner - Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Roy Buchanan - JMP Securities Operator Thank you for standing. And welcome to the iBio Fiscal Year 2022 Results Conference Call. At this time, all participants are in a listen-o ...

iBlo Growing Tomorrow's Biologics CORPORATE PRESENTATION May 2022 Tom Isett, Chairman & CEO © 2022 iBio, Inc. All Rights Reserved. Forward-Looking Statements Certain statements in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or s ...

iBio, Inc. (NYSE:IBIO) Q3 2022 Results Conference Call May 12, 2022 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman and Chief Executive Officer Rob Lutz - Chief Financial and Business Officer Conference Call Participants Roy Buchanan - JMP Securities Operator Good day and thank you for standing. Welcome to the iBio Fiscal 2022 Third Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, t ...

iBio, Inc. (NYSE:IBIO) Q2 2022 Earnings Conference Call February 14, 2022 4:30 PM ET Company Participants Stephen Kilmer - Investor Relations Tom Isett - Chairman and Chief Executive Officer Martin Brenner - Chief Scientific Officer Rob Lutz - Chief Financial and Business Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Roy Buchanan - JMP Securities Matthew Herm - Matthew Herm LLC Philip Barnett - Private Investor Operator Ladies and gentlemen, thank you for standing by and welcome to ...

iBio, Inc. (NYSE:IBIO) Q3 2021 Earnings Conference Call November 16, 2021 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Thomas Isett – Chairman and Chief Executive Officer Martin Brenner – Chief Scientific Officer Randy Maddux – Chief Operating Officer Robert Lutz – Chief Financial and Business Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Norman Carlyle – Private investor Philip Barnett – Shareholder David Sandrock – Private Investor Operator Good day and tha ...

iBio, Inc. (NYSE:IBIO) Q4 Fiscal 2021 Earnings Conference Call September 27, 2021 8:30 AM ET Company Participants Thomas Isett – Chairman & Chief Executive Officer Stephen Kilmer – Investor Relations Randy J Maddux – Chief Operating Officer Martin Brenner – Chief Scientific Officer Robert Lutz – Chief Financial and Business Officer Conference Call Participants Rick – Cantor Fitzgerald Matthew Herm – Matthew Herm LLC Operator Ladies and gentlemen, thank you for standing by and welcome to the iBio fiscal 2021 ...